Evidence map›Paper›PMID 36441829›Full record

ArticlePLoS pathogens2022

High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire.

Iga Kucharska, Špela Binter, Rajagopal Murugan, Stephen W Scally, Julia Ludwig, Katherine Prieto, Elaine Thai, Giulia Costa, Kan Li, Gillian Q Horn and 11 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. RNA and protein immunization withFrontiers in cellular and infection microbiology · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 4 countries.

Iga KucharskaProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada.
Špela BinterKymab Ltd., The Bennet Building (B930) Babraham Research Campus, Cambridge, United Kingdom.
Rajagopal MuruganB Cell Immunology, German Cancer Research Institute (DKFZ), Heidelberg, Germany.
Stephen W ScallyProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada.
Julia LudwigB Cell Immunology, German Cancer Research Institute (DKFZ), Heidelberg, Germany.
Katherine PrietoProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada.
Elaine ThaiProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada.
Giulia CostaVector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
Kan LiDepartment of Surgery, Immunology, Molecular Genetics and Microbiology, Center for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Gillian Q HornDepartment of Surgery, Immunology, Molecular Genetics and Microbiology, Center for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Yevel Flores-GarciaDepartment of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Alexandre BoschProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada.
Taylor SicardProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada.
John L RubinsteinProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada.
Fidel ZavalaDepartment of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
S Moses DennisonDepartment of Surgery, Immunology, Molecular Genetics and Microbiology, Center for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Georgia D TomarasDepartment of Surgery, Immunology, Molecular Genetics and Microbiology, Center for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Elena A LevashinaVector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
Paul KellamKymab Ltd., The Bennet Building (B930) Babraham Research Campus, Cambridge, United Kingdom.
Hedda WardemannB Cell Immunology, German Cancer Research Institute (DKFZ), Heidelberg, Germany.
Jean-Philippe JulienProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada.ORCID 0000-0001-7602-3995
Duke University · USHospital for Sick Children · CAUniversity of Toronto · CAGerman Cancer Research Center · DEJohns Hopkins University · USKymab (United Kingdom) · GBMax Planck Institute for Infection Biology · DE

Funding

High-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0M
NIH HHS S10 OD012289
6 · The paper itself

Abstract

Antibodies targeting the human malaria parasite Plasmodium falciparum circumsporozoite protein (PfCSP) can prevent infection and disease. PfCSP contains multiple central repeating NANP motifs; some of the most potent anti-infective antibodies against malaria bind to these repeats. Multiple antibodies can bind the repeating epitopes concurrently by engaging into homotypic Fab-Fab interactions, which results in the ordering of the otherwise largely disordered central repeat into a spiral. Here, we characterize IGHV3-33/IGKV1-5-encoded monoclonal antibody (mAb) 850 elicited by immunization of transgenic mice with human immunoglobulin loci. mAb 850 binds repeating NANP motifs with picomolar affinity, potently inhibits Plasmodium falciparum (Pf) in vitro and, when passively administered in a mouse challenge model, reduces liver burden to a similar extent as some of the most potent anti-PfCSP mAbs yet described. Like other IGHV3-33/IGKV1-5-encoded anti-NANP antibodies, mAb 850 primarily utilizes its HCDR3 and germline-encoded aromatic residues to recognize its core NANP motif. Biophysical and cryo-electron microscopy analyses reveal that up to 19 copies of Fab 850 can bind the PfCSP repeat simultaneously, and extensive homotypic interactions are observed between densely-packed PfCSP-bound Fabs to indirectly improve affinity to the antigen. Together, our study expands on the molecular understanding of repeat-induced homotypic interactions in the B cell response against PfCSP for potently protective mAbs against Pf infection.

Indexed as

MalariaMalaria, FalciparumMalaria VaccinesAnimalsAntibodies, MonoclonalAntibodies, ProtozoanCryoelectron MicroscopyHumansMiceMice, TransgenicPlasmodium falciparumProtozoan ProteinsAntibodies, MonoclonalAntibodies, ProtozoanMalaria VaccinesProtozoan Proteins

Identifiers

PMID36441829
PMCPMC9762590
OpenAlexW4310089979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.